| IV Iron (mg/mo, average over 3 months)a | p valueb | ||
---|---|---|---|---|
0 | <300 | ≥300 | ||
Study sample | ||||
 Patients, N | 2800 | 3749 | 2922 |  |
 Patients, % | 30 | 40 | 30 |  |
 Region, row % |  |  |  |  |
  North America | 29 | 41 | 30 | 0.94 |
  Europe and Australia/New Zealand | 30 | 37 | 32 | 0.94 |
Demographics | ||||
 Age, years | 64.0 | 64.0 | 63.5 | 0.06 |
 BMI, kg/m2 | 27.0 | 27.5 | 27.9 | <.01 |
 Male, % | 57 | 58 | 58 | 0.47 |
 Black, within US only, % | 33 | 31 | 29 | <.01 |
 Duration on dialysis, years | 4.7 | 4.1 | 3.0 | <.01 |
 Catheter, % | 25 | 29 | 39 | <.01 |
Comorbidities, %: | ||||
 Diabetes | 47 | 51 | 54 | <.01 |
 Hypertension | 85 | 83 | 84 | 0.53 |
 Coronary Heart Disease | 37 | 36 | 35 | 0.16 |
 Cerebrovascular Disease | 13 | 14 | 14 | 0.77 |
 Congestive Heart Failure | 30 | 30 | 28 | 0.80 |
 Peripheral Vascular Disease | 26 | 25 | 25 | 0.22 |
 Other Cardiovascular | 25 | 25 | 26 | 0.59 |
 Cancer (non-skin) | 13 | 11 | 13 | 0.87 |
 GI Bleed (within 12 months) | 4 | 4 | 5 | 0.23 |
 Lung Disease | 13 | 13 | 13 | 0.77 |
 Neurologic Disease | 10 | 9 | 9 | 0.19 |
 Psychiatric Disorder | 17 | 16 | 15 | 0.20 |
 Recurrent Cellulitis or Gangrene | 9 | 10 | 9 | 0.89 |
Laboratory Values (at month 0) | ||||
 Albumin, g/dL | 3.79 | 3.77 | 3.68 | <.01 |
 Creatinine, mg/dL | 8.3 | 8.0 | 7.5 | <.01 |
 White Blood Cells, x 103/uL | 7.0 | 7.0 | 7.2 | <.01 |
 TSAT, % | 31.5 | 29.0 | 23.8 | <.01 |
 Ferritin, ng/mL | 687 | 538 | 441 | <.01 |
 Hemoglobin, g/dL | 11.6 | 11.5 | 11.2 | <.01 |
 CRP, mg/Lc | 12.7 | 11.9 | 15.8 | 0.35 |
Medication Doses (3-month average) | ||||
 IV Iron, mg/month | 0 | 170 | 523 |  |
 ESA, IV epoetin equivalent units/week | 10759 | 11426 | 16101 | <.01 |